Angiotensin II antagonists

This invention provides pharmaceutical heterocyclic derivatives of the formula in which R3 are specified nitrogen-containing fused rings. They antagonize angiotensin II receptors in mammals.

Saved in:
Bibliographic Details
Main Authors LIFER, SHERRYL LYNN, PALKOWITZ, ALAN DAVID, BOYD, DONALD BRADFORD, STEINBERG, MITCHELL IRVIN, MARSHALL, WINSTON STANLEY, PFEIFER, WILLIAM, REEL, JON KEVIN, SIMON, RICHARD LEE, VASUDEVAN, VENKATRAGHAVAN, THRASHER, KENNETH JEFF, WHITESITT, CELIA ANN
Format Patent
LanguageEnglish
French
German
Published 13.08.2003
Edition7
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention provides pharmaceutical heterocyclic derivatives of the formula in which R3 are specified nitrogen-containing fused rings. They antagonize angiotensin II receptors in mammals.
Bibliography:Application Number: EP19930304266